Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Yusuf, Menda"'
Autor:
Spenser S. Johnson, Dijie Liu, Jordan T. Ewald, Claudia Robles-Planells, Casey Pulliam, Keegan A. Christensen, Khaliunaa Bayanbold, Brian R. Wels, Shane R. Solst, M. Sue O’Dorisio, Yusuf Menda, Douglas R. Spitz, Melissa A. Fath
Publikováno v:
Cancer Biology & Therapy, Vol 25, Iss 1 (2024)
Thioredoxin Reductase (TrxR) functions to recycle thioredoxin (Trx) during hydroperoxide metabolism mediated by peroxiredoxins and is currently being targeted using the FDA-approved anti-rheumatic drug, auranofin (AF), to selectively sensitize cancer
Externí odkaz:
https://doaj.org/article/c5a3742216384e1498585e82c931ad1b
Autor:
Islam Ahmed Shehata Elhelf, Ravishankar Pillenahalli Maheshwarappa, MBBS, Jared Hodgson, Christina K. Hodgson, Janet Pollard, Yusuf Menda
Publikováno v:
Radiology Case Reports, Vol 14, Iss 11, Pp 1360-1363 (2019)
Hemangiomas are the most common benign lesions involving the spine. Metastasis is the most common malignant condition. The diagnosis of typical hemangiomas on conventional CT and MRI imaging is straightforward. However, when the hemangiomas are very
Externí odkaz:
https://doaj.org/article/3b2793676b86482f83738ba7f302390a
Autor:
Spenser S. Johnson, Dijie Liu, Jordan T. Ewald, Claudia Robles-Planells, Khaliunaa Bayanbold, Brian R. Wels, Shane R. Solst, M. Sue O’Dorisio, Bryan G. Allen, Yusuf Menda, Douglas R. Spitz, Melissa A. Fath
Publikováno v:
bioRxiv
Thioredoxin Reductase (TrxR) is a key enzyme in reactive oxygen species (ROS) detoxification and in redox regulation. Because cancer cells produce increased steady-state levels of ROS (i.e., superoxide and hydrogen peroxide), TrxR is viable target in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db2b29a43eee17c37e62aa5bb71f97e
https://doi.org/10.1101/2023.05.07.539772
https://doi.org/10.1101/2023.05.07.539772
Publikováno v:
Seminars in Nuclear Medicine. 52:467-474
Radiopharmaceuticals used for cancer therapy are highly selective, designed to kill malignant cells and spare healthy tissues. Side effect rates are generally less than other treatments, but it is still the utmost concern to minimize normal organ tox
Autor:
Michael K. Schultz, Dijie Liu, Mengshi Li, Brianna S. Cagle, Zhiming Dai, Dongyoul Lee, Kelly Orcutt, Edwin Sagastume, Nicholas J. Baumhover, Ivy Vance, Amos Hedt, Yusuf Menda, Frances L. Johnson
Publikováno v:
Endocrine Abstracts.
Autor:
David L. Bushnell, M. Sue O'Dorisio, K D Zamba, Thomas M. O'Dorisio, Janet H Pollard, Mark T. Madsen, Yusuf Menda
Publikováno v:
Cancer Biother Radiopharm
Background: Histone deacetylase (HDAC) inhibitors have been shown in preclinical studies to upregulate norepinephrine transporters in neuroblastoma and pheochromocytoma, and somatostatin receptors in pulmonary carcinoid, small cell lung cancer, and p
Autor:
Chandana Nagaraj, Manish Ora, Girish Bathla, Michael M. Graham, Yusuf Menda, Jitender Saini, Laura L Boles, Neetu Soni
Publikováno v:
Neuroradiol J
Neurodegenerative diseases (NDDs) are characterized by progressive neuronal loss, leading to dementia and movement disorders. NDDs broadly include Alzheimer’s disease, frontotemporal lobar degeneration, parkinsonian syndromes, and prion diseases. T
Autor:
Michael King Schultz, Yusuf Menda, Dijie Liu, Mengshi Li, Frances Johnson, Brianna Cagle, Nicholas Baumhover, Ivy Vance
Publikováno v:
Cancer Research. 83:5049-5049
Objective: Pb-203 and Pb-212 have emerged as a promising elementally-matched theranostic pair for imaging-guided alpha-particle radiotherapy for cancer. A somatostatin receptor 2 (SSTR2)-targeted peptide coupled with novel Pb specific chelator (PSC)
Autor:
Melissa A. Fath, Dijie Liu, Claudia Robles-Planells, Jordan T. Ewald, Keegan A. Christensen, Spenser S. Johnson, Stephen A. Graves, Douglas R. Spitz, Yusuf Menda, M. Sue O’Dorisio
Publikováno v:
Cancer Research. 83:5034-5034
Introduction/Background: Atypical lung carcinoids and lung neuroendocrine carcinomas (NECs) are currently incurable. Most of these cancers express the C-X-C chemokine receptor 4 (CXCR4), making CXCR4 an attractive target for cancer diagnosis and trea
Autor:
Stephen A. Graves, Yusuf Menda, David L. Bushnell, Thomas M. O'Dorisio, Kellie L. Bodeker, M. Sue O'Dorisio, Gideon K. D. Zamba, Mark T. Madsen
Publikováno v:
Journal of Nuclear Medicine. 62:1274-1277
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for metastatic neuroendocrine tumors. Delivering a sufficient tumor radiation dose remains challenging because of critical-organ dose limitations. Adding 131I-metaiodobenzylguanid